MEDIFAST INC
No SEC Form 4 filings for $MED in the last 30 days.
Medifast (NYSE: MED) shares rose 37.5% after Q2 results beat expectations and the company issued a stronger full-year outlook. Medifast reported a $0.28 per-share loss versus a $0.65 expected loss, and revenue of $76.38 million. It guided full-year GAAP EPS of $1.00 at the midpoint, versus analyst estimates.
Medifast (NYSE:MED) reported Q2 CY2026 revenue of $76.38M, down 27.6% year over year but 5.1% above expectations. Next-quarter revenue guidance was $70M at the midpoint, about 3.4% above analyst estimates. GAAP EPS loss was $0.28, worse than consensus. Shares rose 12.8% to $10.99.
Medifast (NYSE: MED) will report Q2 results Monday after market hours. The prior quarter revenue was $76.04 million, down 34.3% year over year, and EPS guidance for next quarter exceeded analysts’ expectations. For the upcoming quarter, analysts expect revenue down 31.1% year over year. MED shares are down 10.9% over the past month; average price target is $12 vs $9.83.
Over the past 7 days, alphai's AI scored 3 news stories mentioning MED (MEDIFAST INC). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent MED coverage spans financial news and earnings.
The earnings beat plus a sharply higher-than-expected GAAP EPS outlook is the immediate driver of repricing, with follow-through risk if margins or demand do not support the forecast.
The article’s new, decision-relevant inputs are the Q2 beat, the next-quarter revenue midpoint, and the GAAP EPS loss versus consensus, all tied to an immediate +12.8% move.
Earnings timing and consensus expectations create a near-term catalyst for MED, but the article provides no new post-close figures yet.
This is a pre-earnings setup with consensus numbers, which can drive positioning into the Aug 03 after-hours print.
Insider purchase indicates confidence in Medifast's future prospects, which could support short-term price appreciation. However, the company's weak financial health and mixed earnings report temper this optimism.
alphai scores every news story that mentions MED with an AI model for sentiment and relevance, and aggregates insider trades from MEDIFAST INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Medifast (NYSE: MED) shares rose 37.5% after Q2 results beat expectations and the company issued a stronger full-year outlook. Medifast reported a $0.28 per-share loss versus a $0.65 expected loss, and revenue of $76.38 million. It guided full-year GAAP EPS of $1.00 at the midpoint, versus analyst estimates.
4 min readMedifast (NYSE:MED) reported Q2 CY2026 revenue of $76.38M, down 27.6% year over year but 5.1% above expectations. Next-quarter revenue guidance was $70M at the midpoint, about 3.4% above analyst estimates. GAAP EPS loss was $0.28, worse than consensus. Shares rose 12.8% to $10.99.
3 min readMedifast (NYSE: MED) will report Q2 results Monday after market hours. The prior quarter revenue was $76.04 million, down 34.3% year over year, and EPS guidance for next quarter exceeded analysts’ expectations. For the upcoming quarter, analysts expect revenue down 31.1% year over year. MED shares are down 10.9% over the past month; average price target is $12 vs $9.83.
4 min readMedifast Inc. (MED) is scheduled to report Q2 2026 earnings on Aug. 3 after the market closes, with results expected at 4:05 PM ET. The consensus estimates call for revenue of $72.70 million and EPS of -$0.65 for the quarter, according to the article.
1 min readMedifast director Scott Schlackman recently purchased 5,000 shares of company stock in two transactions totaling $62,950, increasing his direct holdings to over 30,500 shares. These purchases occurred as Medifast's stock has risen 17.7% year-to-date, despite a weak financial health rating. The company also recently reported mixed Q1 2026 earnings, beating EPS estimates but missing revenue projections.
2 min readMedifast Inc. (MED) has released its earnings summary for the quarter that ended on March 31. This report provides key financial performance indicators for the company during that period. The full details are available through Thomson Reuters.
2 min readMedifast (NYSE:MED) is scheduled to release its Q1 2026 earnings after market close on Monday, April 27th, with analysts expecting a loss of ($0.55) per share on $69.20 million in revenue. The company recently posted Q4 results where it beat analyst estimates, reporting ($0.55) EPS for the quarter. Several analysts have adjusted their ratings and price targets for Medifast, with a consensus "Reduce" rating and a $12.00 target price.
2 min readStephens has lowered its price target for Medifast (NYSE:MED) stock to $12 from $15, while maintaining an Equal Weight rating, citing margin pressures despite exceeding revenue expectations for Q4 2025. The company faces ongoing challenges from GLP-1 adoption and a value-focused consumer impacting client acquisition. Medifast's future performance hinges on stabilizing coach headcount and successful product refresh initiatives to regain top-line momentum.
4 min readMED's third-quarter results reflect pressure from fewer active OPTAVIA Coaches, but it is steering toward metabolic health for growth.
4 min readMED boosts growth efforts with new products, digital tools and an expanded OPTAVIA coaching network.
3 min read
